Related Experiment Videos
Update on overactive bladder: pharmacologic approaches on the horizon
1Division of Urology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. erovner@mail.med.upenn.edu
Current Urology Reports
|September 23, 2003
Summary
New pharmacologic treatments for overactive bladder are emerging, addressing limitations in current therapies. Initial studies show promise, but large-scale trials are needed to confirm efficacy and tolerability of these novel agents.
Area of Science:
- Pharmacology
- Urology
- Drug Development
Background:
- Current pharmacologic therapies for overactive bladder (OAB) have limitations in efficacy and tolerability.
- An ideal therapeutic agent for OAB has yet to be identified.
Purpose of the Study:
- To review emerging pharmacologic treatments for overactive bladder.
- To assess novel approaches in drug delivery and agent types.
Main Methods:
- Review of clinical development pipeline for OAB pharmacotherapies.
- Analysis of initial study data for novel anticholinergics and other agents.
- Comparison of emerging agents with existing OAB treatments.
Main Results:
- Several new pharmacologic treatments for OAB are in clinical development.
- These include novel anticholinergics and agents utilizing new drug delivery systems.
- Initial studies suggest some new agents may be comparable or superior to existing therapies.
Conclusions:
- The landscape of overactive bladder pharmacotherapy is evolving with new agents.
- Promising initial results require validation through large-scale, well-controlled clinical trials.
- Further research is necessary to determine the long-term efficacy and tolerability of these novel OAB treatments.